SEC Form 4 · accession 0000059478-17-000239
ELI LILLY & Co · LLY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Susan Mahony
Officer — SVP & Pres., Lilly Oncology
Period of report
Dec 4, 2017
Accepted (ET)
Dec 5, 2017 · 5:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000059478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 4, 2017 | S | 36,585 | $86.18 | D | 54,885 | D | |
| Common Stock | Nov 3, 2017 | G | 15,861 | $0.00 | D | 39,024 | D | |
| Common Stock | holding | — | — | — | 1,726 | I | 401(k) | |
| Common StockF3 | holding | — | — | — | 1,715 | I | 401(k) - by husband | |
| Common StockF3 | holding | — | — | — | 13,509 | I | by husband |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $85.39 to $86.71. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Reporting person disclaims beneficial ownership of these shares.